Changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate

Journal of Bone and Mineral Metabolism

Volumn 25, Issue 2, 2007, Pages 142-146

  Takada, Junichi ^a   Iba, Kousuke ^b   Imoto, Kenshi ^a   Yamashita, Toshihiko ^b  

^a Chitose City Hospital   (Japan)

^b SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

Alendronate; Bisphosphonate; Bone marker; NTX; Risedronate

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; RISEDRONIC ACID;

ABDOMINAL DISTENSION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; FRACTURE; HIGH RISK POPULATION; HUMAN; JAPAN; JAPANESE; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH DISCOMFORT; TREATMENT DURATION; UPPER ABDOMINAL PAIN; URINALYSIS;

AGED; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; COLLAGEN TYPE I; ETIDRONIC ACID; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTORS;

EID: 33847271658     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-006-0739-3     Document Type: Article

References (24)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy 2001 Thiazide use and reduced sodium intake for prevention of osteoporosis JAMA 285 785 795
2. PD Delmas E Seeman 2004 Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy Bone (NY) 34 599 604
3. P Garnero P Dargent-Molina D Hans AM Schott G Breart 1998 Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study Osteoporos Int 8 563 569
4. RA Hannon R Eastell 2003 Biochemical markers of bone turnover and fracture prediction J Br Menopause Soc 9 10 15
5. O Bruyere J Collette P Delmas A Rouillon C Roux 2003 Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women Maturities 44 259 265
6. R Eastell I Barton RA Hannon A Chines P Garnero 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate J Bone Miner Res 18 1051 1056
7. SR Cummings DM Black DE Thompson WB Applegate E Barrett-Connor 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture intervention Trial JAMA 280 2077 2082
8. DM Black DE Thompson DC Bauer K Ensrud MCT Musliner 2000 Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group J Clin Endocrinol Metab 85 4118 4124
9. J Reginster HW Minne OH Sorensen M Hooper C Roux 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group Osteoporos Int 11 83 91
10. ST Harris NB Watts HK Genant CD [tmp] McKeever T Hangartner 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group JAMA 282 1344 1352
11. K Kushida M Shiraki T Nakamura H Kishimoto H Morii 2004 Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: 3-year follow-up study J Bone Miner Metab 22 462 468
12. K Kushida M Fukunaga H Kishimoto M Shiraki A Itabashi 2004 A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial J Bone Miner Metab 22 469 478
13. Y Nishizawa T Nakamura H Ohta K Kushida I Gorai 2005 Guideline for the use of biochemical markers of bone turnover in osteoporosis (2004) J Bone Miner Metab 23 97 104
14. FA [tmp] McAlister A Laupacis GA Wells DL Sackett 1999 Users' guides to the medical literature: XIX. Applying clinical trial results. B. Guidelines for determining whether a drug is exerting (more than) a class effect JAMA 282 1371 1377
15. HC Bucher GH Guyatt DJ Cook A Holbrook FA [tmp] McAlister 1999 Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate endpoints. Evidence based medicine working group JAMA 282 771 778
16. S Sarkar JY Reginster GG Crans A Diez-Perez KV Pinette 2004 Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk J Bone Miner Res 19 394 401
17. DC Bauer DM Black P Garnero M Hochberg S Ott 2004 Changes in bone turnover and hip, nonspine, and vertebral fracture in alendronate-treated women: the fracture intervention trial J Bone Miner Res 19 1250 1258
18. MC Hochberg S Greenspan RD Wasnich P Miller DE Thompson 2002 Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents J Clin Endocrinol Metab 87 1586 1592
19. NH Bjarnason S Sarkar T Duong B Mitlak PD Delmas 2001 Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis Osteoporos Int 12 922 930
20. Y Ogura A Gonsho JC Cyong H Orimo 2004 Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies J Bone Miner Metab 22 111 119
21. D Hosking S Adami D Felsenberg J Cannata Andia M Valimaki 2003 Comparison of change in bone resorption and bone mineral density with once weekly alendronate and daily risedronate: a randomized placebo-controlled study Curr Med Res Opin 19 383 394
22. A Cranney G Guyatt L Griffith G Wells P Tugwell 2002 Meta-analyses of therapies for postmenopausal osteoporosis. IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis Endocr Rev 23 570 577
23. CJ Rosen MC Hochberg SL Bonnick M [tmp] McClung P Miller 2005 Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study J Bone Miner Res 20 141 151
24. JA Kanis A Oden O Johnell F Caulin H Bone 2002 Uncertain future of trials in osteoporosis Osteoporos Int 13 443 449